Kewaunee Scientific (KEQU) AI Stock Analysis

• Market Cap: $126.12M
• Dividend Yield: N/A
• Average Volume (3M): 12.63K
• Price to Earnings (P/E): 10.6
• Beta (1Y): 0.65
• Revenue Growth: 30.09%
• EPS Growth: -33.19%
• Country: US
• Employees: 1,006
• Sector: Consumer Cyclical
• Sector Strength: 84
• Industry: Furnishings, Fixtures & Appliances
• EPS (TTM): 1.04
• Shares Outstanding: 2,865,694
• 10 Day Avg. Volume: 24,481
• 30 Day Avg. Volume: 12,635
• PEG Ratio: -0.20
• Price to Book (P/B): 1.41
• Price to Sales (P/S): 0.38
• P/FCF Ratio: 7.18
• Enterprise Value/Market Cap: 1.75
• Enterprise Value/Revenue: 0.84
• Enterprise Value/Gross Profit: 2.86
• Enterprise Value/Ebitda: 9.27
• 1Y Price Target: $44.00
• Price Target Upside: -0.02% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 57 Neutral
• Price Target: $44.00 ▼(-0.02% Downside)

Kewaunee Scientific's overall stock score is primarily influenced by its solid financial performance, which is offset by bearish technical indicators. The stock's undervaluation offers potential upside, but the lack of dividend yield and negative market momentum are significant concerns.

Kewaunee Scientific Business Overview & Revenue Model

Company Description

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. It operates through two segments, Domestic and International. The company's products include steel, wood, laminate furniture, fume hoods, biological safety cabinets, laminar flow and ductless hoods, adaptable modular and column systems, moveable workstations and carts, epoxy resin worksurfaces, sinks, and accessories and related design services. Its laboratory products are used in chemistry, physics, biology, and other general science laboratories in the pharmaceutical, biotechnology, industrial, chemical, commercial, educational, government, and health care markets; technical products are used in facilities manufacturing computers and light electronics and by users of computer and networking furniture; and laminate caseworks that are used in educational, healthcare, and industrial applications. The company sells its products primarily through dealers, its subidiaries, and a national distributor. Kewaunee Scientific Corporation was founded in 1906 and is headquartered in Statesville, North Carolina.

How the Company Makes Money

Kewaunee Scientific generates revenue through the sale of its laboratory furniture and equipment, which are sold to a diverse client base including educational institutions, hospitals, and research facilities. The company operates on a direct sales model, supplemented by distributors and representatives, allowing it to reach a broad market. Key revenue streams include custom laboratory installations, standard product sales, and ongoing maintenance and service contracts. Kewaunee also benefits from strategic partnerships with construction and design firms that integrate its products into new laboratory builds and renovations, further enhancing its market presence and revenue potential.

Kewaunee Scientific Financial Statement Overview

Summary

Kewaunee Scientific shows strong revenue growth and improved profitability metrics, with a solid equity base. However, increasing leverage and past cash flow volatility require careful management.

Income Statement

Kewaunee Scientific has shown strong revenue growth, increasing from $147.5M in 2020 to $240.5M in 2025, highlighting a robust growth trajectory. Gross profit margins have improved significantly over the years, with a notable increase in EBIT and EBITDA margins, reflecting enhanced operational efficiency. However, net profit margin has fluctuated, indicating some volatility in bottom-line profitability despite the upward trend.

Balance Sheet

The company's debt-to-equity ratio has increased, indicating higher leverage, but remains manageable within industry norms. Stockholders' equity has grown, supporting a stable equity ratio. Return on equity has improved significantly, driven by rising net income, which suggests strengthening shareholder value. However, the rising debt levels could be a potential risk if not managed carefully.

Cash Flow

Kewaunee Scientific has experienced volatility in cash flow from operations, with recent improvements in free cash flow growth. The operating cash flow to net income ratio indicates healthy cash generation relative to earnings. The free cash flow conversion is positive, but past years showed negative free cash flow, suggesting potential liquidity pressures during those periods. Continuous improvement in cash flow management is essential.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	263.18M	240.47M	203.75M	219.49M	168.87M	147.47M
Gross Profit	77.30M	68.86M	52.05M	35.59M	24.22M	23.99M
EBITDA	23.85M	22.76M	18.04M	8.16M	916.00K	459.00K
Net Income	12.30M	11.40M	18.75M	1.36M	-6.00M	-3.61M
Balance Sheet
Total Assets	193.49M	194.65M	134.77M	118.90M	118.77M	89.38M
Cash, Cash Equivalents and Short-Term Investments	19.49M	14.94M	23.27M	8.08M	4.43M	5.21M
Total Debt	18.34M	50.16M	11.00M	12.92M	9.44M	16.15M
Total Liabilities	124.62M	128.41M	78.56M	80.41M	82.59M	47.90M
Stockholders Equity	68.87M	64.46M	54.76M	37.41M	35.69M	41.24M
Cash Flow
Free Cash Flow	18.71M	12.62M	15.19M	-7.94M	-9.79M	-1.49M
Operating Cash Flow	21.37M	14.78M	19.56M	-3.79M	-7.88M	912.00K
Investing Cash Flow	-31.39M	-30.90M	-4.37M	-4.15M	-1.91M	-2.40M
Financing Cash Flow	5.61M	7.41M	-3.01M	14.93M	11.03M	1.98M

Kewaunee Scientific Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 44.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KEQU, the sentiment is Negative. The current price of 44.01 is below the 20-day moving average (MA) of 51.67, below the 50-day MA of 54.56, and below the 200-day MA of 49.38, indicating a bearish trend. The MACD of -2.93 indicates Positive momentum. The RSI at 32.59 is Neutral, neither overbought nor oversold. The STOCH value of 18.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KEQU.

Kewaunee Scientific Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ETD	77 Outperform	744.43M	14.54	10.70%	6.56%	-4.89%	-19.26%
LZB	64 Neutral	1.39B	15.44	9.01%	2.61%	2.18%	-22.35%
KEQU	57 Neutral	$126.12M	10.64	19.99%	―	30.09%	-33.19%
BSET	55 Neutral	140.42M	56.82	1.48%	4.95%	-7.22%	0.00%
HOFT	52 Neutral	114.49M	-8.70	-6.12%	8.64%	-6.46%	-1110.82%
SNBR	46 Neutral	188.54M	-4.56	8.62%	―	-14.40%	-2.14%
Sector *	61 Neutral	$18.38B	12.79	-2.54%	3.03%	1.52%	-15.83%

Kewaunee Scientific Corporate Events

Kewaunee Scientific Appoints J. Jette Campbell to Board

On September 10, 2025, Kewaunee Scientific Corporation appointed J. Jette Campbell to its Board of Directors, effective immediately. Campbell, a seasoned advisor with extensive experience in financial restructuring and business strategy, is expected to bring valuable insights to Kewaunee as it focuses on accelerating growth. His appointment aligns with the company’s strategic objectives to expand its global footprint and pursue transformative growth opportunities. Additionally, the Board approved amendments to its Bylaws, setting the number of directors between five and nine.

The most recent analyst rating on (KEQU) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on Kewaunee Scientific stock, see the KEQU Stock Forecast page.

Kewaunee Scientific Holds Annual Shareholder Meeting

On August 27, 2025, Kewaunee Scientific Corporation held its Annual Meeting of Shareholders, where key decisions were made regarding the re-election of Class III directors, the ratification of Forvis Mazars, LLP as auditors for fiscal year 2026, and the advisory approval of executive compensation. The shareholders agreed to continue holding an annual advisory vote on executive compensation, aligning with the Board’s recommendation, which may impact the company’s governance and stakeholder engagement strategies.

The most recent analyst rating on (KEQU) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on Kewaunee Scientific stock, see the KEQU Stock Forecast page.

Kewaunee Scientific to Announce Q1 FY26 Results

On August 27, 2025, Kewaunee Scientific Corporation announced its plan to release the first quarter fiscal year 2026 financial results on September 10, 2025, after the close of trading. This announcement is significant as it provides stakeholders with insights into the company’s financial health and performance for the quarter, potentially impacting its market positioning and investor confidence.

The most recent analyst rating on (KEQU) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on Kewaunee Scientific stock, see the KEQU Stock Forecast page.

Kewaunee Scientific Acquires NuAire, Expands Market Presence

Kewaunee Scientific Corporation held its Annual Meeting of Shareholders virtually on August 27, 2025, where it presented its fiscal year 2025 financial review and strategic direction, including the acquisition of NuAire, Inc. The company’s net sales increased from $203.8 million in FY 2024 to $240.5 million in FY 2025, although net earnings attributable to the corporation decreased from $18.8 million to $11.4 million. The acquisition of NuAire, a leading manufacturer of biosafety cabinets, is expected to expand Kewaunee’s market presence in healthcare, biomedical, and vivarium sectors.

The most recent analyst rating on (KEQU) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on Kewaunee Scientific stock, see the KEQU Stock Forecast page.